Editas Medicine Inc.

EDIT | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.83

+$0.13 (+4.81%)

At close: Sep 21, 2026, 4:00 PM ET

$2.87

+$0.04 (+1.28%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.81%

(1D)

Rating

Updated: Sep 1, 2026

43.5

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $434.3M

1D Range

2.70 2.89

52W Range

1.66 4.54

Valuation (TTM)

PE -3.77

PB 4.13

EV/EBITDA -3.39

Valuation (NTM)

Forward PE N/A

Forward PEG 0.56

Price Target $4

Cash Flow

FCF Yield -33.1%

SBC Adj. FCF Yield -35.6%

SBC Impact -7.5%

Margins

Gross Margin 56.9%

Operating Margin -174.7%

FCF Margin -305.7%

Growth (CAGR)

Revenue 3Y | 5Y 34.5% | -10.3%

Dil EPS 3Y | 5Y 40.5% | 16.6%

FCF 3Y | 5Y 8.0% | 1.0%

Returns

ROA -31.1%

ROE -196.6%

ROIC -46.8%

Financial Health

Net Cash

$211.65M

Current Ratio 3.19

Interest Coverage 39.05

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene edi...

Sector Healthcare

Industry Biotechnology

Employees 87

IPO Date Feb 2, 2016

Website www.editasmedicine.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 9, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+41.34%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞